From lymphopenia to restoration : IL-7 immunotherapy for lymphocyte recovery in glioblastoma
Copyright © 2024 Elsevier B.V. All rights reserved..
Glioblastoma, the most prevalent malignant primary brain tumor, presents substantial treatment challenges because of its inherent aggressiveness and limited therapeutic options. Lymphopenia, defined as reduced peripheral blood lymphocyte count, commonly occurs as a consequence of the disease and its treatment. Recent studies have associated lymphopenia with a poor prognosis. Factors that contribute to lymphopenia include radiotherapy, chemotherapy, and the tumor itself. Patients who are female, older, using dexamethasone, or receiving higher doses of radiation therapy are particularly vulnerable to this condition. Several preclinical studies have explored the use of interleukin-7, a crucial cytokine for lymphocyte homeostasis, to restore lymphocyte counts and potentially rebuild the immune system to combat glioblastoma cells. With the development of recombinant interleukin-7 for prolonged activity in the body, various clinical trials are underway to explore this treatment in patients with glioblastoma. Our study provides a comprehensive summary of the incidence of lymphopenia, its potential biological background, and the associated clinical risk factors. Furthermore, we reviewed several clinical trials using IL-7 cytokine therapy in glioblastoma patients. We propose IL-7 as a promising immunotherapeutic strategy for glioblastoma treatment. We are optimistic that our study will enhance understanding of the complex interplay between lymphopenia and glioblastoma and will pave the way for the development of more effective treatment modalities.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:588 |
---|---|
Enthalten in: |
Cancer letters - 588(2024) vom: 28. Apr., Seite 216714 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kim, Joonseok [VerfasserIn] |
---|
Links: |
---|
Themen: |
Glioblastoma |
---|
Anmerkungen: |
Date Completed 09.04.2024 Date Revised 09.04.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.canlet.2024.216714 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368590682 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM368590682 | ||
003 | DE-627 | ||
005 | 20240409232449.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240219s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.canlet.2024.216714 |2 doi | |
028 | 5 | 2 | |a pubmed24n1370.xml |
035 | |a (DE-627)NLM368590682 | ||
035 | |a (NLM)38369003 | ||
035 | |a (PII)S0304-3835(24)00107-1 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Kim, Joonseok |e verfasserin |4 aut | |
245 | 1 | 0 | |a From lymphopenia to restoration |b IL-7 immunotherapy for lymphocyte recovery in glioblastoma |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 09.04.2024 | ||
500 | |a Date Revised 09.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
520 | |a Glioblastoma, the most prevalent malignant primary brain tumor, presents substantial treatment challenges because of its inherent aggressiveness and limited therapeutic options. Lymphopenia, defined as reduced peripheral blood lymphocyte count, commonly occurs as a consequence of the disease and its treatment. Recent studies have associated lymphopenia with a poor prognosis. Factors that contribute to lymphopenia include radiotherapy, chemotherapy, and the tumor itself. Patients who are female, older, using dexamethasone, or receiving higher doses of radiation therapy are particularly vulnerable to this condition. Several preclinical studies have explored the use of interleukin-7, a crucial cytokine for lymphocyte homeostasis, to restore lymphocyte counts and potentially rebuild the immune system to combat glioblastoma cells. With the development of recombinant interleukin-7 for prolonged activity in the body, various clinical trials are underway to explore this treatment in patients with glioblastoma. Our study provides a comprehensive summary of the incidence of lymphopenia, its potential biological background, and the associated clinical risk factors. Furthermore, we reviewed several clinical trials using IL-7 cytokine therapy in glioblastoma patients. We propose IL-7 as a promising immunotherapeutic strategy for glioblastoma treatment. We are optimistic that our study will enhance understanding of the complex interplay between lymphopenia and glioblastoma and will pave the way for the development of more effective treatment modalities | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Glioblastoma | |
650 | 4 | |a Immunotherapy | |
650 | 4 | |a Interleukin-7 | |
650 | 4 | |a Lymphopenia | |
650 | 7 | |a Interleukin-7 |2 NLM | |
700 | 1 | |a Choi, Haeyoun |e verfasserin |4 aut | |
700 | 1 | |a Jeun, Sin-Soo |e verfasserin |4 aut | |
700 | 1 | |a Ahn, Stephen |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancer letters |d 1976 |g 588(2024) vom: 28. Apr., Seite 216714 |w (DE-627)NLM000147273 |x 1872-7980 |7 nnns |
773 | 1 | 8 | |g volume:588 |g year:2024 |g day:28 |g month:04 |g pages:216714 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canlet.2024.216714 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 588 |j 2024 |b 28 |c 04 |h 216714 |